MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress
Topline results from Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected…
Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL)
CHICAGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company…
Rakovina Therapeutics Announces Debentureholder Approval of Debenture Extension, Expiry of Warrant Incentive Program
November 28, 2025 20:13 ET | Source: Rakovina Therapeutics Inc VANCOUVER, British…
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 28, 2025 08:00 ET | Source: Spero Therapeutics, Inc. CAMBRIDGE, Mass.,…
Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors
BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq:…
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025
November 18, 2025 16:30 ET | Source: Protara Therapeutics NEW YORK, Nov.…
Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results
CAMBRIDGE, Mass., Nov. 12, 2025 /PRNewswire/ -- Cypherpunk Technologies Inc., previously known as…
Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy
Khing Oei appointed Chairman of the Board; Will McEvoy appointed Chief Investment…
Ernexa Therapeutics to Present at Oxford Globals Cell 2025
Sanjeev Luther, President and CEO to give an oral presentation and participate…
Halia Therapeutics to Present Groundbreaking Data on Novel Allosteric NEK7 Inhibitor Ofirnoflast at the 2025 American Society of Hematology Annual Meeting
- Data demonstrates ofirnoflast's efficacy in myelodysplastic syndrome (MDS) with robust and…
